Clinical Efficacy of Tianwang Buxindan Treatment on Atrial Fibrillation Combined with Coronary Heart Disease with Yin Deficiency and Fire Prosperity

WANG Guang-yan; TENG Ming-zi; ZHU Jun

doi:10.13422/j.cnki.syfjx.20181735

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Tianwang Buxindan Treatment on Atrial Fibrillation Combined with Coronary Heart Disease with Yin Deficiency and Fire Prosperity

更新时间：2024-01-04

- Clinical Efficacy of Tianwang Buxindan Treatment on Atrial Fibrillation Combined with Coronary Heart Disease with Yin Deficiency and Fire Prosperity
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 17, Pages: 189-194(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20181735
  CLC： R541.75;R541.4
- Published：2018
- 稿件说明：
移动端阅览
WANG Guang-yan, TENG Ming-zi, ZHU Jun. Clinical Efficacy of Tianwang Buxindan Treatment on Atrial Fibrillation Combined with Coronary Heart Disease with Yin Deficiency and Fire Prosperity[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 189-194.
DOI：

WANG Guang-yan, TENG Ming-zi, ZHU Jun. Clinical Efficacy of Tianwang Buxindan Treatment on Atrial Fibrillation Combined with Coronary Heart Disease with Yin Deficiency and Fire Prosperity[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(17): 189-194. DOI： 10.13422/j.cnki.syfjx.20181735.

摘要

目的：探讨天王补心丹加减治疗心房颤动合并冠心病（阴虚火旺证）的临床疗效及抗炎作用机制。方法：将118例患者随机按数字表法以1：1比例分为对照组和观察组各59例。对照组口服华法林钠片，2.5~5 mg·d-1，1次/d，监测国际标准化比值（INR）2.0~3.0；口服琥珀酸美托洛尔缓释片，23.75~47.5 mg，1次/d；口服阿托伐他汀钙片，20 mg·d-1，1次/晚。观察组在对照组治疗的基础加服天王补心丹加减，1剂/d。两组疗程均为连续治疗8周。进行治疗前后动态心电图和超声心动图检查[记录左室射血分数（LVEF），心输出量（CO），左室收缩末内径（LVESD）和每搏输出量（SV）]；进行心悸阴虚火旺证评分；检测治疗前后甘油三酯（TG），总胆固醇（TC），高密度脂蛋白（HDL-C）和低密度脂蛋白（LDL-C）水平；检测治疗前后N-末端B型利钠肽原（NT-proBNP），白细胞介素-6（IL-6），肿瘤坏死因子-α（TNF-α），C-反应蛋白（CRP）和单核细胞趋化蛋白-1（MCP-1）；进行治疗前后安全性评价。结果：经秩和检验，治疗后观察组动态心电图疗效优于对照组（P<0.05）；治疗后观察组患者心室率少于对照组（P<0.05）；观察组房颤伴发心电图异常情况少于对照组（χ2=6.631，P<0.05）；观察组心悸、失眠、烦躁、胸闷、胸痛等主要症状评分和次证评分及阴虚火旺证总分均低于对照组（P<0.01）；观察组患者血脂异常例数少于对照组（χ2=4.417，P<0.05）；观察组患者LVEF，CO和SV均高于对照组（P<0.05）；观察组患者NT-proBNP，IL-6，TNF-α，CRP和MCP-1水平低于对照组（P<0.01）。结论：在西医常规治疗的基础上，采用天王补心丹加减治疗冠心病合并房颤可控制心室率，减轻临床症状，调节脂代谢，改善心功能和抑制炎症反应，起到治疗房颤的作用。

Abstract

Objective:To discuss the clinical efficacy of Tianwang Buxindan treatment to atrial fibrillation combined with coronary heart disease (Yin deficiency and fire prosperity) and investigate its mechanism of anti-inflammatory action. Method:One hundred and eighteen patients were randomly divided into control group and observation group by random number table at ratio of 1:1

59 cases in each group. Patients in control group got warfarin sodium tablets

2.5-5.0 mg/days

with international normalized ratio (INR) monitoring for 2.0-3.0 times. Metoprolol succinate sustained-release tablets

23.75-47.5 mg

and atorvastatin calcium tablets

20 mg/days

qd at night. Based on the treatment in control group

the patients in observation group added Tianwang Buxindan treatment

1 dose/day. The treatment course was 8 weeks for both groups. Before and after treatment

electrocardiogram and echocardiography examinations were conducted[left ventricular ejection fraction (LVEF)

cardiac output (CO)

left ventricular end systolic diameter (LVESD)

and stroke volume (SV) were recorded]. Scores of Yin deficiency and fire prosperity were graded; levels of triglyceride (TG)

total cholesterol (TC)

high density lipoprotein (HDL-C)

low density lipoprotein (LDL-C)

NT-pro btype natriuretic peptide (NT-proBNP)

interleukin-6 (IL-6)

tumor necrosis factor-α (TNF-α)

C reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) were detected; and the safety was also evaluated both before and after treatment. Result:In the rank sum test

in observation group were superior to that in control group (P<0.05). After treatment

the ventricular rate in observation group was lower than that in control group (P<0.05)

and the number of atrial fibrillation combined with abnormality of electrocardiogram was lower than that in control group (χ2=6.631

P<0.05). The scores of palpitation

insomnia

irritability

chest tightness

chest pain

scores of the secondary symptoms and total score of Yin deficiency and fire prosperity were all lower than those in control group(P<0.01). Number of cases of dyslipidemia was also lower than that in control group (χ2=4.417

P<0.05). Levels of LVEF

CO and SV in observation group were higher than those in control group (P<0.05)

while the levels of NT-proBNP

IL-6

TNF-α

CRP and MCP-1 were lower than those in control group (P<0.01). During the study

no serious adverse event and hemorrhage happened

and there was no statistical significance in the abnormality of liver and kidney function and clotting routine. Conclusion:Based on the treatment of routine western medicine treatment

Tianwang Buxindan treatment can control ventricular rate

relieve clinical symptoms

regulate lipid metabolism

ameliorate heart function and inhibit inflammatory reaction

which is effective for atrial fibrillation.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and Evaluation of Rat Model of Myocardial Ischemia-reperfusion Injury with Phlegm and Blood Stasis Blocking Collaterals Syndrome Based on Metabolomics

Establishment and Evaluation of Rat Model of Acute Myocardial Infarction in Coronary Heart Disease with Qi and Yin Deficiency Syndrome Based on Sleep Deprivation Combined with Coronary Artery Ligation

Mechanism of Xuefu Zhuyutang in Intervening in Ferroptosis in Rats with Coronary Heart Disease with Blood Stasis Syndrome Based on ACSL4 Signalling Pathway

Construction of an Intelligent Diagnosis and Treatment Ontology for Traditional Chinese Medicine Based on Clinical Practice Guidelines：A Case Study of Coronary Heart Disease

Research Progress on Pathogenesis of Ankylosing Spondylitis and Intervention of Traditional Chinese Medicine： A Review

Related Author

HU Longxiao

GAO Jiabei

MA Weihao

LU Jieming

GAO Yunxiao

YUAN Yue

ZHANG Qiuyan

CHEN Xiaoxiao

Related Institution

School of Clinical Medicine，Beijing University of Chinese Medicine

Beijing Key Laboratory of Chinese Materia Pharmacology，National Clinical Research Center of Traditional Chinese Medicine for Cardiovascular Diseases，Institute of Basic Medical Sciences， Xiyuan Hospital，China Academy of Chinese Medical Sciences

Natural History Museum of China

Institute of Basic Medical Sciences，Xiyuan Hospital，China Academy of Chinese Medical Sciences

Hunan University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰